information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and, (d) ways to minimize the burden of the collection of information upon the respondents, including the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and included in the Agency's subsequent request for OMB approval of the proposed information collection. All comments will become a matter of public record.

Dated: June 22, 2009.

#### Carolyn M. Clancy,

Director.

[FR Doc. E9-15086 Filed 6-29-09; 8:45 am]

BILLING CODE 4160-90-P

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Agency for Healthcare Research and Quality

Agency Information Collection Activities: Proposed Collection; Comment Request

**AGENCY:** Agency for Healthcare Research and Quality, HHS.

**ACTION:** Notice.

SUMMARY: This notice announces the intention of the Agency for Healthcare Research and Quality (AHRQ) to request that the Office of Management and Budget (OMB) approve the proposed information collection project: "Health IT Community Tracking Study 2009." In accordance with the Paperwork Reduction Act of 1995, 44 U.S.C. 3506(c)(2)(A), AHRQ invites the public to comment on this proposed information collection.

**DATES:** Comments on this notice must be received by August 31, 2009.

**ADDRESSES:** Written comments should be submitted to: Doris Lefkowitz, Reports Clearance Officer, AHRQ, by email at *doris.lefkowitz@ahrq.hhs.gov*.

Copies of the proposed collection plans, data collection instruments, and specific details on the estimated burden can be obtained from the AHRQ Reports Clearance Officer.

#### FOR FURTHER INFORMATION CONTACT:

Doris Lefkowitz, AHRQ Reports Clearance Officer, (301) 427–1477, or by e-mail at *doris.lefkowitz@ahrq.hhs.gov*.

#### SUPPLEMENTARY INFORMATION:

#### **Proposed Project**

Health IT Community Tracking Study 2009

Electronic prescribing (e-prescribing) is a central focus of efforts to promote health information technology (IT) and is of particular interest to AHRQ because of its potential to improve patient safety by reducing medication errors. Despite many public- and private-sector initiatives to support eprescribing, to date, physician adoption and use has been limited (Friedman, Schueth and Bell 2009). Recently, section 132 of the Medicare Improvements for Patients and Providers Act of 2008 (MIPPA), Public Law 110-275, authorized a new incentive program for eligible individual providers who are successful e-prescribers. In addition, section 4101 of the American Recovery and Reinvestment Act of 2009 (ARRA), Public Law 111–5, provides incentives for meaningful use of electronic health record technology, which includes the use of e-prescribing.

The potential gains from e-prescribing assume that prescribers and pharmacists have access to the required features and use them. Limited research on the topic suggests, however, that not all eprescribing systems currently have the full range of e-prescribing features required under MIPPA; that even when the features are available, physician practices face barriers to implementing them effectively; and even when they are implemented at the practice level, physicians may not use them. For example, in a small, exploratory qualitative study by Grossman, et al. (2005), physicians did not routinely have access to patient medication histories or formulary data for a significant portion of their patients and when they did, physicians often did not use the information, instead continuing to rely on patients for medication history and pharmacists to identify formulary issues. Several studies have identified that IT system limitations, workflow and training issues, and real or perceived regulatory barriers present obstacles in both the physician and pharmacy settings to electronic transmission of prescriptions (Grossman et al. 2007; NORC 2007; Rupp and Warholak 2008; Warholak and Rupp 2009).

AHRQ proposes to conduct a qualitative research study designed to help build knowledge on how the e-prescribing features required under MIPPA are actually being implemented and used by physicians and pharmacies in 12 nationally representative communities. These communities have

been studied longitudinally since the mid-1990s as part of the Center for Studying Health System Change (HSC) Community Tracking Study (CTS) (Center for Studying Health System Change 2007). This qualitative study will collect data from physician practices and pharmacies that are using electronic transmission of prescriptions to allow a focus on both the facilitators of and barriers to this critical aspect of e-prescribing. The study will be the first to ask questions of physician practices and pharmacies in the same communities on the same topics, providing a much more complete picture of e-prescribing implementation. For example, in addition to gaining physician and pharmacy perspectives on electronic transmission, the study will explore how physician practices use patient formulary data and how pharmacies perceive changes in the communication with physician practices around formulary issues with e-prescribing.

Information collected by this study will inform strategies to promote the adoption and effective use of eprescribing being developed by AHRQ and other Department of Health and Human Services agencies, including the Centers for Medicare & Medicaid Services (CMS) and the Office of the National Coordinator for Health IT, as well as State and local governments and private health care organizations. In particular, while physician adoption has been the focus of most policy efforts, findings from the study can help identify and shape strategies to promote more effective implementation of eprescribing in retail and mail-order pharmacies. This work will be conducted by AHRQ's contractor, the Center for Studying Health System Change (HSC), under contract number 290-05-0007-03. This study is being conducted pursuant to AHRQ's statutory authority to conduct and support research on health care and systems for the delivery of such care, including activities with respect to health care technologies, facilities and equipment, 42 U.S.C. 299a(a)(5).

#### **Method of Collection**

The study will use qualitative methods, including telephone interviews with physician practices and pharmacies, as well as State pharmacy associations, IT vendors and other eprescribing experts. Using semistructured interview protocols, the following specific research questions will be addressed to provide an in-depth look at unexplored barriers to effective e-prescribing use in physician practices and pharmacies, including:

- · How are physicians using thirdparty information in making prescribing decisions, including patient medication history, generic drug information, and patient-specific formulary data?
- How are physician practices and retail and mail-order pharmacies using e-prescribing systems to communicate electronically with each other?
- What are the most common reasons that physician practices and pharmacies communicate about prescriptions generated by physician e-prescribing systems (regardless of how they were sent)?
- What are the facilitators of and challenges to implementing eprescribing features that support physician access to third-party information in making prescribing decisions and features that support electronic communication between physician practices and pharmacies?
- What are the perceived effects of having access to e-prescribing features that support physician access to thirdparty information in making prescribing decisions and features that support electronic communication between physician practices and pharmacies on physician practice and pharmacy operations, physician prescribing behavior and patient outcomes?
- What are the implications for policy efforts to promote e-prescribing?

#### **Estimated Annual Respondent Burden**

Interviews will be conducted at a total of 110 organizations over the two years of this project. Within each of the 24 participating physician practices (12 annually), two interviews will be conducted: one with the medical director or physician-user best able to describe practice processes for eprescribing, who will provide a clinical

perspective (Interview Protocol 2), and a second with an IT administrator or office manager, who can provide a technical and operational perspective (Interview Protocol 1). The other 86 organizations will each have only one interview, for a total of 43 additional interviews annually. Eight different organization-specific interview protocols have been developed, with response times ranging from 30 minutes to 1 hour.

Exhibit 1 shows the estimated annual burden hours for each organization's time to participate in this research. The total annual burden is estimated to be 57 hours.

Exhibit 2 shows the estimated annual cost burden associated with the organizations' time to participate in this research. The total annual burden is estimated to be \$3,004.

#### EXHIBIT 1—ESTIMATED ANNUALIZED BURDEN HOURS

Form name	Number of organizations*	Number of responses per organization	Hours per response	Total burden hours
Interview Protocol 1—Physician Practice IT Administrator or Office Manager  Interview Protocol 2—Physician Practice Medical Director or Physician Practice Medical Director or Physician Practice Medical Director or Physic	12	1	30/60	6
sician User	12	1	45/60	9
Interview Protocol 3—Pharmacy Pharmacist-In-Charge	28	1	1	28
Interview Protocol 4—State Pharmacy Association Representative	6	1	1	6
Interview Protocol 5—Pharmacy IT Vendor Representative Interview Protocol 6—E-prescribing System Vendor Representa-	1	1	1	1
tive	3	1	1	3
Vendor Representatives	3	1	1	3
Interview Protocol 8—Other E-prescribing Experts	2	1	30/60	1
Total	67	NA	NA	57

The estimated total number of unique organizations participating in each year of the study is 55 since Interview Protocols 1 and 2 will both be administered to respondents in physician practices.

#### EXHIBIT 2—ESTIMATED ANNUALIZED COST BURDEN

Form name	Number of organizations*	Total burden hours	Average hourly wage rate**	Total cost burden
Interview Protocol 1—Physician Practice IT Administrator or Office Manager	12	6	32.62	\$196
Interview Protocol 2—Physician Practice Medical Director or Physician User	12 28	9 28	80.42 48.09	724 1,347
Interview Protocol 4—State Pharmacy Association Representative	6 1	6 1	49.89 54.75	299 55
Interview Protocol 6—E-prescribing System Vendor Representative	3	3	54.75	164
Vendor Representatives	3 2	3 1	54.75 54.75	164 55
Total	67	57	NA	3,004

\*The estimated total number of unique organizations participating in each year of the study is 55 since Interview Protocols 1 and 2 will both be

administered to respondents in physician practices.

\*\*Wage rates were calculated using the mean hourly wage from the U.S. Department of Labor, Bureau of Labor Statistics, May 2007 National Occupational Employment and Wage Estimates for the United States, Occupational Employment Statistics (OES), Washington, DC (Feb. 2009), 
http://www.bls.gov/oes/2007/may/oes\_nat.htm (accessed April 2009). Wage rate for Interview Protocol 3—Pharmacy Pharmacist-In-Charge reflects the weighted average for retail and mail order pharmacists (\$47.58 per hour) and pharmacy chain representatives (\$54.75 per hour).

### **Estimated Annual Costs to the Federal Government**

The estimated total cost to the Federal Government for this project is \$374,635

over a two-year period from February 2, 2009 to February 1, 2010. The estimated average annual cost is \$187,318. Exhibit 3 provides a breakdown of the estimated

total and average annual costs by category.

#### EXHIBIT 3—ESTIMATED TOTAL AND ANNUAL COST\* TO THE FEDERAL GOVERNMENT

Cost component	Total cost	Annualized cost
Project Development and Project Management  Data Collection Activities  Data Analysis  Publication and Dissemination of Results	\$87,783 141,048 55,884 89,920	\$43,892 70,524 27,942 44,960
Total	374,635	187,318

<sup>\*</sup>Costs are fully loaded including overhead and G&A.

#### **Request for Comments**

In accordance with the above-cited Paperwork Reduction Act legislation, comments on AHRO's information collection are requested with regard to any of the following: (a) Whether the proposed collection of information is necessary for the proper performance of AHRQ health care research, quality improvement and information dissemination functions, including whether the information will have practical utility; (b) the accuracy of AHRQ's estimate of burden (including hours and costs) of the proposed collection(s) of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information upon the respondents, including the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and included in the Agency's subsequent request for OMB approval of the proposed information collection. All comments will become a matter of public record.

Dated: June 22, 2009.

#### Carolyn M. Clancy,

Director.

[FR Doc. E9–15089 Filed 6–29–09; 8:45 am]

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### **National Institutes of Health**

#### Breast Cancer and Environmental Research Act of 2008; Delegation of Authority

Notice is hereby given that I have delegated to the Director, National Institutes of Health (NIH), the authorities under Section 2 of the Breast Cancer and Environmental Research Act of 2008, Public Law 110–354, as amended, which amends Subpart 1 of Part C of Title IV of the Public Health Service Act by adding Section 417F, authorizing the establishment of the Interagency Breast Cancer and Environmental Research Coordinating Committee. I am also delegating the authority under Section 417F of the Public Health Service Act, as amended, to select both voting and nonvoting members of the Committee and to review the necessity of the Committee in the year 2011 and, thereafter, at least once every two years.

This delegation shall be exercised in accordance with the Department's applicable policies, procedures, guidelines, and regulations.

In addition, I ratified and affirmed any actions taken by the NIH Director or his subordinates which involved the exercise of the authorities delegated herein prior to the effective date of this delegation.

This delegation is effective upon date of signature.

Dated: June 23, 2009.

#### Kathleen Sebelius,

Secretary.

[FR Doc. E9–15439 Filed 6–29–09; 8:45 am] **BILLING CODE 4140–01–M** 

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Agency for Healthcare Research and Quality

Meeting of the National Advisory Council for Healthcare Research and Quality Subcommittee on Quality Measures for Children's Healthcare in Medicaid and Children's Health Insurance Programs (CHIP)

**AGENCY:** Agency for Healthcare Research and Quality (AHRQ), Department of Health and Human Services.

**ACTION:** Notice of public meeting.

SUMMARY: In accordance with section 10(a) of the Federal Advisory Committee Act, 5 U.S.C. App. 2, this notice announces a meeting of the National Advisory Council for Healthcare Research and Quality Subcommittee on Quality Measures for Children's Healthcare in Medicaid and Children's Health Insurance Programs (CHIP).

**DATES:** The meeting will be held on Wednesday, July 22, 2009, from 10 a.m. to 5 p.m. and Thursday, July 23, 2009 from 9 a.m. to 5 p.m.

**ADDRESSES:** Holiday Inn Capitol, 550 C Street, SW., Washington, DC 20024.

# FOR FURTHER INFORMATION CONTACT: Padmini Jagadish, Public Health Analyst at the Agency for Healthcare Research

at the Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, Maryland 20850, (301) 427– 1927. For press-related information, please contact Karen Migdail at (301) 427–1855.

If sign language interpretation or other reasonable accommodation for a disability is needed, please contact Mr. Michael Chew, Director, Office of Equal Employment Opportunity Program, Program Support Center, on (301) 443–1144, no later than July 3, 2009.

#### SUPPLEMENTARY INFORMATION:

#### I. Purpose

The National Advisory Council for Healthcare Research and Quality was established in accordance with section 921 (now section 931) of the Public Health Service Act, 42 U.S.C. 299c. In accordance with its statutory mandate, the Council is to advise the Secretary of the Department of Health and Human Services and the Director, Agency for Healthcare Research and Quality (AHRQ), on matters related to actions of AHRQ to enhance the quality, and improve the outcomes of health care services; improve access to such services through scientific research; and promote improvements in clinical practice and in the organization,